Ztalmy-Ganaxolone
CDKL5 deficiency disorder causes severe, early-onset, treatment-resistant seizures, and management relied entirely on off-label antiseizure medicines. Ztalmy (ganaxolone) was the first therapy approved for it. Ganaxolone is a neuroactive steroid that positively modulates both synaptic and extrasynaptic GABA-A receptors, strengthening inhibitory signaling more broadly than conventional benzodiazepines. The oral suspension treats seizures associated with cyclin-dependent […]
Vonjo-Pacritinib
Myelofibrosis patients with severe thrombocytopenia were effectively excluded from JAK inhibitor therapy, since dose reductions for low platelets undermined efficacy. Vonjo (pacritinib) was approved specifically for them. Pacritinib inhibits JAK2 and IRAK1 while largely sparing JAK1, allowing full dosing without the additional myelosuppression that limits other agents in this population. The twice-daily capsule treats adults […]
Pyrukynd-Mitapivat
Pyruvate kinase deficiency causes lifelong hemolytic anemia managed with transfusions and splenectomy, neither of which corrects the underlying enzyme defect. Pyrukynd (mitapivat) was the first therapy to do so. As an allosteric activator of the pyruvate kinase enzyme, it restores glycolytic ATP production in red blood cells, improving their stability and survival rather than only […]
Cibinqo-Abrocitinib
Oral JAK inhibitors offered atopic dermatitis patients rapid itch relief in pill form, arriving alongside the injectable biologics. Cibinqo (abrocitinib) is the JAK1-selective entrant. Abrocitinib is a selective JAK1 inhibitor that interrupts signaling from multiple itch and inflammation cytokines at once, producing faster symptom relief than antibody therapies typically achieve. The once-daily tablet is approved […]
Quviviq-Daridorexant
Insomnia treatment long depended on GABA-acting hypnotics carrying dependence and next-day impairment concerns. Quviviq (daridorexant) belongs to the newer orexin-targeting generation designed around those issues. As a dual orexin receptor antagonist, it blocks the wake-promoting orexin signal rather than broadly sedating the central nervous system, and its half-life was selected to limit residual morning effects. […]
Leqvio-Inclisiran
PCSK9 antibodies proved that deep LDL lowering was achievable, but fortnightly injections and payer resistance limited their reach. Leqvio (inclisiran) changed the dosing interval dramatically. Unlike PCSK9 antibodies that bind the circulating protein, Leqvio silences PCSK9 messenger RNA inside the liver, which is why a subcutaneous injection twice yearly suffices after two starter doses. It […]
Cytalux-Pafolacianine
Surgeons removing ovarian cancer rely on sight and touch to find every deposit, and microscopic residual disease drives recurrence. Cytalux (pafolacianine) made some of that tissue visible. Injected before surgery, it binds folate receptor alpha, overexpressed on many ovarian tumors, and fluoresces under near-infrared light so surgeons can detect lesions that inspection alone would miss. […]
Livtencity-Maribavir
Cytomegalovirus reactivation after transplant is dangerous, and resistance or intolerance to ganciclovir-based therapy leaves clinicians with toxic fallback options. Livtencity (maribavir) offered a different target. Maribavir inhibits the viral UL97 protein kinase, blocking CMV DNA replication, encapsidation, and nuclear egress through a target distinct from the DNA polymerase other antivirals attack. The oral tablet treats […]
Voxzogo-Vosoritide
Achondroplasia had no approved treatment addressing its cause, leaving limb-lengthening surgery as the main intervention. Voxzogo (vosoritide) targeted the signaling defect directly. By binding NPR-B, this C-type natriuretic peptide analog counteracts the overactive FGFR3 signaling that suppresses chondrocyte proliferation in the growth plates. The daily subcutaneous injection improves linear growth in children with achondroplasia who […]
Scemblix-Asciminib
Chronic myeloid leukemia is well served by ATP-competitive TKIs, but resistance mutations and cumulative toxicity still push patients through multiple lines. Scemblix (asciminib) attacks the same kinase from a different site. Unlike the ATP-competitive inhibitors that preceded it, Scemblix binds the ABL myristoyl pocket, making it the first STAMP inhibitor and preserving activity against ATP-site […]
